Lipid immunity in rhesus monkeys and development of a new anti-tuberculosis vaccine
Project/Area Number |
15H04869
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Infectious disease medicine
|
Research Institution | Kyoto University |
Principal Investigator |
SUGITA Masahiko 京都大学, ウイルス・再生医科学研究所, 教授 (80333532)
|
Co-Investigator(Kenkyū-buntansha) |
中村 孝司 北海道大学, 薬学研究院, 助教 (20604458)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥17,680,000 (Direct Cost: ¥13,600,000、Indirect Cost: ¥4,080,000)
Fiscal Year 2017: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
|
Keywords | 結核 / 脂質ワクチン / 感染症 / 細菌 / 脂質 / ワクチン / マクロファージ / 好中球 |
Outline of Final Research Achievements |
Tuberculosis remains to be a global threat to humans. The only currently available anti-tuberculosis vaccine, BCG, has been used for decade, but development of alternative vaccines is definitely required. The principal investigator has attempted to develop a new type of lipid-based vaccines against tuberculosis. In this study, the vaccine candidate lipid was studied extensively in terms of is biosynthesis as well as its immunological properties. The findings obtained in this study provide an important basis for the development of anti-tuberculosis lipid vaccines.
|
Report
(4 results)
Research Products
(7 results)
-
-
-
[Journal Article] Neutrophils and the S100A9 protein critically regulate granuloma formation2016
Author(s)
Yuya Yoshioka, Tatsuaki Mizutani, Satoshi Mizuta, Ayumi Miyamoto, Satoru Murata, Toshiaki Ano, Hiroshi Ichise, Daisuke Morita, Hiroyuki Yamada, Yoshihiko Hoshino, Tatsuaki Tsuruyama and Masahiko Sugita
-
Journal Title
Blood Advances
Volume: 1
Issue: 3
Pages: 184-192
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-